Document Classification

Section Type: RESULTS

Text: There were no statistically significant differences between the 2 study arms with regard to : 1) peripheral neurotoxicity, as assessed using both the EORTC-QLQ-CIPN20 (P =. 21) and the CTCAE scales (P =. 449 for grade 2 neurotoxicity ; P =. 039 for time to development of grade 2 neuropathy, in favor of the placebo) ; 2) the degree of paclitaxel acute pain syndrome (P =. 30 for patients who received paclitaxel every 3-4 weeks and P =. 002, in favor of the placebo, for patients who received weekly paclitaxel) ; 3) the time to disease progression (P =. 63) ; or 4) apparent toxicities.